Suppr超能文献

用于日本雪松花粉症经皮免疫治疗的油包固纳米分散体

Solid-in-Oil Nanodispersions for Transcutaneous Immunotherapy of Japanese Cedar Pollinosis.

作者信息

Kong Qingliang, Kitaoka Momoko, Wakabayashi Rie, Tahara Yoshiro, Kamiya Noriho, Goto Masahiro

机构信息

Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, Fukuoka 819-0395, Japan.

Advanced Transdermal Drug Delivery System Center, Kyushu University, Fukuoka 819-0395, Japan.

出版信息

Pharmaceutics. 2020 Mar 7;12(3):240. doi: 10.3390/pharmaceutics12030240.

Abstract

Japanese cedar pollinosis (JCP) is a common affliction caused by an allergic reaction to cedar pollen and is considered a disease of national importance in Japan. Antigen-specific immunotherapy (AIT) is the only available curative treatment for JCP. However, low compliance and persistence have been reported among patients subcutaneously or sublingually administered AIT comprising a conventional antigen derived from a pollen extract. To address these issues, many research studies have focused on developing a safer, simpler, and more effective AIT for JCP. Here, we review the novel antigens that have been developed for JCP AIT, discuss their different administration routes, and present the effects of anti-allergy treatment. Then, we describe a new form of AIT called transcutaneous immunotherapy (TCIT) and its solid-in-oil (S/O) nanodispersion formulation, which is a promising antigen delivery system. Finally, we discuss the applications of S/O nanodispersions for JCP TCIT. In this context, we predict that TCIT delivery by using a S/O nanodispersion loaded with novel antigens may offer an easier, safer, and more effective treatment option for JCP patients.

摘要

日本雪松花粉症(JCP)是一种由对雪松花粉的过敏反应引起的常见疾病,在日本被视为具有国家重要性的疾病。抗原特异性免疫疗法(AIT)是JCP唯一可用的治愈性治疗方法。然而,据报道,皮下或舌下给予包含源自花粉提取物的传统抗原的AIT的患者中,依从性和持续性较低。为了解决这些问题,许多研究致力于为JCP开发更安全、更简单且更有效的AIT。在此,我们综述了已为JCP AIT开发的新型抗原,讨论了它们不同的给药途径,并介绍了抗过敏治疗的效果。然后,我们描述了一种称为经皮免疫疗法(TCIT)的新型AIT形式及其油包固(S/O)纳米分散体制剂,这是一种有前景的抗原递送系统。最后,我们讨论了S/O纳米分散体在JCP TCIT中的应用。在这种情况下,我们预测使用负载新型抗原的S/O纳米分散体进行TCIT递送可能为JCP患者提供一种更简便、更安全且更有效的治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1130/7150915/dd1585d398b9/pharmaceutics-12-00240-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验